A head‐to‐head comparison of plasma biomarkers to detect Alzheimer's disease in a memory clinic
Year: 2025
Type: article
Study design: Observational Study
Abstract: INTRODUCTION: Blood-based biomarkers for Alzheimer's disease (AD) have been widely studied, but direct comparisons of several biomarkers in clinical settings remain limited. METHODS: In this cross-sectional study, plasma biomarkers from 197 participants in the BIODEGMAR cohort (Hospital del Mar, Barcelona) were analyzed. Participants were classified based on AD cerebrospinal fluid (CSF) core biomarkers. We assessed the ability of plasma p-tau181, p-tau217, p-tau231, t-tau, and Aβ42/40 to classify Aβ pathology status. RESULTS: Plasma p-tau biomarkers had a greater diagnostic performance and larger effect sizes compared to t-tau and Aβ42/40 assays in detecting Aβ pathology. Among them, plasma p-tau217 consistently outperformed the others, demonstrating superior area under the curves. Furthermore, p-tau217 showed the strongest correlation between plasma and CSF levels, underscoring its potential as a reliable surrogate for CSF biomarkers. DISCUSSION: Several plasma biomarkers, targeting different epitopes and using different platforms, demonstrated high performance in detecting AD in a memory clinic setting. HIGHLIGHTS: Plasma p-tau biomarkers demonstrated higher diagnostic performance and larger effect sizes than t-tau and Aβ42/40 assays in detecting Alzheimer's disease. Among the p-tau biomarkers, p-tau217 assays consistently outperformed the others, providing superior classification of Aβ pathology status across different phosphorylation sites. p-tau217 assays showed the strongest correlation between plasma and CSF levels, indicating its potential as a reliable surrogate for CSF biomarkers. Several plasma p-tau biomarkers can be used in a specialized memory clinic to accurately detect Alzheimer's disease.
Source: Alzheimer s & Dementia
DOI: 10.1002/alz.14609
Authors: Federica Anastasi, Aida Fernández‐Lebrero, Nicholas J. Ashton, Paula Ortiz‐Romero, Javier Torres‐Torronteras, Armand González‐Escalante, Marta Milà‐Alomà, José Contador, Greta García‐Escobar, Rosa María Manero‐Borràs, Irene Navalpotro‐Gómez, Esther Jiménez‐Moyano, Aparna Sahajan, Qinyu Hao, Bingqing Zhang, Andreas Jeromin, Nathalie Le Bastard, Alicia Nadal, Tahmine Mousavi, Gwendlyn Kollmorgen, Margherita Carboni, Oriol Grau‐Rivera, Henrik Zetterberg, Marta del Campo, Kaj Blennow, Albert Puig‐Pijoan, Marc Suárez‐Calvet
Institutions: Pasqual Maragall Foundation, Barcelonaβeta Brain Research Center, Barcelona Institute of Science and Technology, Centre for Genomic Regulation, Hospital del Mar Research Institute, Universitat Pompeu Fabra, Hospital Del Mar, King's College London, Banner Sun Health Research Institute, Banner Alzheimer’s Institute, University of Gothenburg, University of California, San Francisco, Fujirebio (Belgium), Meso Scale Discovery (United States), Roche (Switzerland), Roche Diagnostics International AG (Switzerland), Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, University of Wisconsin System, University of Wisconsin–Madison, Sahlgrenska University Hospital, UK Dementia Research Institute, UCL Queen Square Institute of Neurology, University College London, Universidad San Pablo CEU, Sorbonne Université, Pitié-Salpêtrière Hospital, Institut du Cerveau, Universitat Autònoma de Barcelona
Language: English
Subfield: Psychiatry and Mental health
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,200
Funders: Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Familjen Erling-Perssons Stiftelse, Cure Alzheimer's Fund, “la Caixa” Foundation, Stiftelsen för Gamla Tjänarinnor, EU Joint Programme – Neurodegenerative Disease Research, Ministerio de Ciencia, Innovación y Universidades, National Institute for Health and Care Research, University College London, European Commission, Generalitat de Catalunya, Hjärnfonden, Vetenskapsrådet, UK Dementia Research Institute, Fundación Bancaria Caixa d'Estalvis i Pensions de Barcelona, Horizon 2020 Framework Programme, HORIZON EUROPE Framework Programme, Instituto de Salud Carlos III, Agencia Estatal de Investigación, National Institute on Aging, H2020 European Research Council
Awards: G1023825524, G1057200632, G1088883541, G1255325603, G1360698832, G1428335294, G150733400, G1551449788, G1588116593, G176366027, G1771944843, G1802301745, G1833008592, Junior Leader la Caixa Postdoctoral Fellowship Programme: Shaping the new generation of leaders in research, G1970163327, G201353144, G2057385626, G237833635, G2543812357, G2772962269, G2799940023, G292763017, G3039816778, G3041725664, G3241251457, Fluid biomarkers for neurodegenerative dementias, G3480869486, G3903502641, G3914690605, G4234328627, G4260843567, G432431387, G434337789, G4377393254, G4794845420, Identification of age-related Human Blood factors as a therapeutic target for Alzheimer's disease, G4937468798, G4993383890, G5040492720, G506008078, G5065677113, G5099673792, G5132640529, G516766298, Fluid biomarkers for neurodegenerative dementias, G5783601166, CASCADE: CAuSe or Consequence in Alzheimer DiseasE?, G6158734006, G6289970089, G6343838365, G6470304958, Multi-omics Interdisciplinary Research Integration to Address DEmentia diagnosis, G6745400708, G683931746, G691317373, G7084143925, G7564620063, G7685134749, G7731791180, G7759009890, El impacto clínico de los nuevos biomarcadores sanguíneos de Alzheimer: el estudio PLASMAR, G7944295140, Factores sanguíneos pro-rejuvenecimiento y pro-envejecimiento en la enfermedad de Alzheimer preclínica y su efecto en la estructura cerebral y la cognición, G8824911526, Arizona Alzheimer's Disease Research Center
OpenAlex ID: W4407945145